Tissue-specific promoters in gene therapy for the treatment of prostate cancer

Citation
T. Shirakawa et al., Tissue-specific promoters in gene therapy for the treatment of prostate cancer, MOL UROL, 4(2), 2000, pp. 73-82
Citations number
18
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Urology & Nephrology
Journal title
MOLECULAR UROLOGY
ISSN journal
1091-5362 → ACNP
Volume
4
Issue
2
Year of publication
2000
Pages
73 - 82
Database
ISI
SICI code
1091-5362(200022)4:2<73:TPIGTF>2.0.ZU;2-A
Abstract
Delivery of therapeutic toxic genes to and their expression in tumor cells through the use of tissue-specific promoters could decrease their toxic eff ect on neighboring normal cells when virus-mediated gene delivery results i n their infection. We have demonstrated the utility of two prostate cancer- specific promoters, long PSA and osteocalcin, for tissue-specific toxic gen e therapy for prostate cancer. The two promoters were highly active in both androgen-dependent and androgen-independent prostate cancer cells. We also introduce the Phase I trial of osteocalcin promoter-based toxic gene thera py for bone metastases of prostate cancer, which is in progress at the Univ ersity of Virginia.